Clear Search

Showing 1 result for “Siddiqi TJ” published 2022.

March 2022

Early Benefit With Empagliflozin in Heart Failure With Preserved Ejection Fraction: Insights From the EMPEROR-Preserved Trial

Eur J Heart Fail 2022;24(2):245–8. doi:10.1002/ejhf.2420

Results reinforce sustained clinical, health status and quality of life benefits with empagliflozin in patients with HF‑pEF, and underscore the need for timely initiation of therapy.

more…